Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 3/2016

01-03-2016 | Research Article

Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients

Authors: L. Ceniceros, J. Aristu, E. Castañón, C. Rolfo, J. Legaspi, A. Olarte, G. Valtueña, M. Moreno, I. Gil-Bazo

Published in: Clinical and Translational Oncology | Issue 3/2016

Login to get access

Abstract

Introduction

Lung cancer is the most frequent neoplasm in humans. Surgery is considered the best therapeutic approach for stage I non-small lung cell cancer (NSCLC). However, a remarkable amount of patients are considered as inoperable. Stereotactic body radiotherapy (SBRT) has risen as an option for those patients, rendering excellent results in quality of life and survival.

Materials and methods

We analyzed clinical studies published between 2002 and 2015 which included SBRT as a treatment modality. Our own clinical series was analyzed as well. The patterns of failure following SBRT were investigated, together with the outcomes and the toxicity observed.

Results

SBRT has proven to maintain an excellent local control. The analysis showed the tumor size and the histology as determinant factors for the response to treatment.

Conclusion

According to the published evidence as well as our own experience, SBRT is a safe and feasible approach for early NSCLC. Its results may be comparable with surgery treatment.
Literature
1.
2.
Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75(3):677–82.CrossRefPubMed
3.
Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Stereotactic body radiotherapy (sbrt) for operable stage i non-small-cell Lung cancer: can sbrt be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81(5):1352–8.CrossRefPubMed
4.
Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010;28(6):928–35.CrossRefPubMed
5.
Joyner M, Salter BJ, Papanikolaou N, Fuss M. Stereotactic body radiation therapy for centrally located lung lesions. Acta Oncol. 2006;45(7):802–7.CrossRefPubMed
6.
Oshiro Y, Aruga T, Tsuboi K, Marino K, Hara R, Sanayama Y, et al. Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol. 2010;186(5):274–9.CrossRefPubMed
7.
Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–9.CrossRefPubMed
8.
Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol. 2011;6(12):2036–43.CrossRefPubMed
9.
Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;72(4):967–71.CrossRefPubMed
10.
Takahashi W, Yamashita H, Omori M, Kitaguchi M, Shibata-Kobayashi S, Sakumi A, et al. The feasibility and efficacy of stereotactic body radiotherapy for centrally-located lung tumors. Anticancer Res. 2013;33(11):4959–64.PubMed
11.
Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol. 2012;7(9):1394–9.CrossRefPubMed
12.
Blanco R, Maestu I, de la Torre MG, Cassinello A, Nuñez I. A review of the management of elderly patients with non-small-cell lung cancer. Ann Oncol. 2015;26(3):451–63.CrossRefPubMed
13.
Pallis AG, Gridelli C, Van Meerbeeck JP, Greillier L, Wedding U, Lacombe D, et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol. 2010;21(4):692–706.CrossRefPubMed
14.
Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol. 2010;94(1):1–11.CrossRefPubMed
15.
Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27(20):3290–6.CrossRefPubMed
16.
Nyman J, Johansson K, Hultén U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer—mature results for medically inoperable patients. Lung Cancer. 2006;51(1):97–103.CrossRefPubMed
17.
McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non–small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63(4):1010–5.CrossRefPubMed
18.
Soliman H, Cheung P, Yeung L, Poon I, Balogh J, Barbera L, et al. Accelerated hypofractionated radiotherapy for early-stage non-small-cell lung cancer: Long-term results. Int J Radiat Oncol Biol Phys. 2011;79(2):459–65.CrossRefPubMed
19.
Atallah S, Cho BCJ, Allibhai Z, Taremi M, Giuliani M, Le LW, et al. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2014;89(3):532–8.CrossRefPubMed
20.
Koto M, Takai Y, Ogawa Y, Matsushita H, Takeda K, Takahashi C, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2007;85(3):429–34.CrossRefPubMed
21.
Hiraoka M, Nagata Y. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the Japanese experience. Int J Clin Oncol. 2004;9:352–5.CrossRefPubMed
22.
Woody NM, Stephans KL, Marwaha G, Djemil T, Videtic GM. Stereotactic body radiation therapy for non-small cell lung cancer Tumors greater than 5 cm: safety and efficacy. Int J Radiat Oncol Biol Phys. 2015;92(2):325–31.CrossRefPubMed
23.
Kong F, Zhao J, Wang J, Faivre-Finn C. Radiation dose effect in locally advanced non-small cell lung cancer. J Thorac Dis. 2014;6(4):336–47.PubMedCentralPubMed
24.
Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I non small cell lung carcinoma. Cancer. 2004;101(7):1623–31.CrossRefPubMed
25.
Takeda A, Sanuki N, Kunieda E, Ohashi T, Oku Y, Takeda T, et al. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys. 2009;73(2):442–8.CrossRefPubMed
26.
Stanic S, Paulus R, Timmerman RD, Michalski JM, Barriger RB, Bezjak A, et al. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early-stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys. 2014;88(5):1092–9.PubMedCentralCrossRefPubMed
27.
Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol. 2014;32(26):2847–54.PubMedCentralCrossRefPubMed
28.
Qiao X, Tullgren O, Lax I, Sirzén F, Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003;41:1–11.CrossRefPubMed
29.
Cheung PCF, Yeung LTF, Basrur V, Ung YC, Balogh J, Danjoux CE. Accelerated hypofractionation for early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;54(4):1014–23.CrossRefPubMed
30.
Ricardi U, Filippi AR, Guarneri A, Giglioli FR, Ciammella P, Franco P, et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer. 2010;68(1):72–7.CrossRefPubMed
31.
Casutt A, Bouchaab H, Beigelman-Aubry C, Bourhis J, Lovis A, Matzinger O. Stereotactic body radiotherapy with helical TomoTherapy for medically inoperable early stage primary and second-primary non-small-cell lung neoplasm: 1-year outcome and toxicity analysis. Br J Radiol. 2015;88(1049):20140687.CrossRefPubMed
32.
Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63(5):1427–31.CrossRefPubMed
33.
Kimura K, Tomita N, Shimizu A, Sato Y, Makita C, Kodaira T. A case of severe hemoptysis after stereotactic body radiotherapy for peripherally located stage I non-small cell lung cancer. Jpn J Radiol. 2015;33(6):370–4.CrossRefPubMed
34.
Zimmermann FB, Geinitz H, Schill S, Grosu A, Schratzenstaller U, Molls M, et al. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer. 2005;48(1):107–14.CrossRefPubMed
35.
Inoue T, Shimizu S, Onimaru R, Takeda A, Onishi H, Nagata Y, et al. Clinical outcomes of stereotactic body radiotherapy for small lung lesions clinically diagnosed as primary lung cancer on radiologic examination. Int J Radiat Oncol Biol Phys. 2009;75(3):683–7.CrossRefPubMed
36.
Videtic GMM, Stephans K, Reddy C, Gajdos S, Kolar M, Clouser E, et al. Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control. Int J Radiat Oncol Biol Phys. 2010;77(2):344–9.CrossRefPubMed
37.
Haidar YM, Rahn DA 3rd, Nath S, Song W, Bazhenova L, Makani S, et al. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation. Ther Adv Respir Dis. 2014;8(1):3–12.CrossRefPubMed
38.
Crabtree T, Puri V, Timmerman R, Fernando H, Bradley J, Decker PA, et al. Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). J Thorac Cardiovasc Surg. 2013;145(3):692–9.CrossRefPubMed
39.
Ottlakan A, Martucci N, Rocco G. Is surgery still the best management option for early stage NSCLC? Transl Lung Cancer Res. 2014;3(3):159.PubMedCentralPubMed
40.
Crabtree TD, Puri V, Robinson C, Bradley J, Broderick S, Patterson GA, et al. Analysis of first recurrence and survival in patients with stage I non-small cell lung cancer treated with surgical resection or stereotactic radiation therapy. J Thorac Cardiovasc Surg. 2014;147(4):1183–91.PubMedCentralCrossRefPubMed
41.
Zheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage i non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2014;90(3):603–11.CrossRefPubMed
42.
Uzel EK, Abacıoğlu U. Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy? Balkan Med J. 2015;32(1):8.PubMedCentralPubMed
43.
Daly ME, Beckett LA, Chen AM. Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? Pract Radiat Oncol. 2014;4(4):240–6.PubMedCentralCrossRefPubMed
44.
Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues GB, Ward A, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)—can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol. 2012;102(3):335–42.CrossRefPubMed
45.
Collins BT, Erickson K, Reichner CA, Collins SP, Gagnon GJ, Dieterich S, et al. Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors. Radiat Oncol. 2007;2:39.PubMedCentralCrossRefPubMed
46.
Brown WT, Wu X, Fayad F, Fowler JF, Amendola BE, García S, et al. CyberKnife radiosurgery for stage I lung cancer: results at 36 months. Clin Lung Cancer. 2007;84(8):88–92.
47.
Collins BT, Vahdat S, Erickson K, Collins SP, Suy S, Yu X, et al. Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer. J Hematol Oncol. 2009;2:1.PubMedCentralCrossRefPubMed
48.
Chen H, Lohr F, Fritz P, Wenz F, Dobler B, Lorenz F, et al. Stereotactic, single-dose irradiation of lung tumors: a comparison of absolute dose and dose distribution between pencil beam and Monte Carlo algorithms based on actual patient CT scans. Int J Radiat Oncol Biol Phys. 2010;78(3):955–63.CrossRefPubMed
49.
Takahashi W, Yamashita H, Saotome N, Iwai Y, Sakumi A, Haga A, et al. Evaluation of heterogeneity dose distributions for stereotactic radiotherapy (SRT): comparison of commercially available Monte Carlo dose calculation with other algorithms. Radiat Oncol. 2012;7:20.PubMedCentralCrossRefPubMed
50.
Latifi K, Oliver J, Baker R, Dilling TJ, Stevens CW, Kim J, et al. Study of 201 non-small cell lung cancer patients given stereotactic ablative radiation therapy shows local control dependence on dose calculation algorithm. Int J Radiat Oncol Biol Phys. 2014;88(5):1108–13.CrossRefPubMed
Metadata
Title
Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients
Authors
L. Ceniceros
J. Aristu
E. Castañón
C. Rolfo
J. Legaspi
A. Olarte
G. Valtueña
M. Moreno
I. Gil-Bazo
Publication date
01-03-2016
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 3/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1361-4

Other articles of this Issue 3/2016

Clinical and Translational Oncology 3/2016 Go to the issue

Research Article

Shorter hemodialysis duration is a risk factor for the recurrence of urothelial carcinoma of the bladder in patients on maintenance hemodialysis

Research Article

Decreased expression of MicroRNA-200 family in human breast cancer is associated with lymph node metastasis

Review Article

Central nervous system niche involvement in the leukemia

Research Article

Prognostic factors affecting survival in metastatic soft tissue sarcoma: an analysis of 110 patients

Research Article

The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy

Research Article

Methylation of ASC/TMS1 promoter is associated with poor prognosis of patients with gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits